Marker Therapeutics (MRKR) Stock Analysis & Winston Score

Marker Therapeutics is a small biotech company focused on developing cancer treatments. It works on a type of therapy called multi-tumor associated antigen T-cell therapy, which uses a patient's own immune cells to fight cancer. The company's main focus is on blood cancers like acute myeloid leukemia (AML) and solid tumors, and its potential customers would be cancer patients and hospitals. The company does not yet sell any approved products, so it earns little to no revenue. It funds its research through equity offerings and grants, which is common for early-stage biotechs. Marker operates primarily in the United States and is very small, with a market cap near zero. Its financial metrics show deep losses, which reflects how much it spends on clinical trials relative to what it earns. The biggest risk is whether its experimental therapies will succeed in clinical trials and eventually win regulatory approval — without that, the company faces serious challenges to its survival.